Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY23
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Glaxosmithkline Pharmaceuticals Ltd (GLAXO) is currently trading at 2,491.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
GlaxoSmithKline Pharmaceuticals Limited (GSK India) is a leading Indian subsidiary of GSK plc that researches, manufactures, markets and distributes prescription pharmaceuticals, vaccines and specialty medicines across General Medicines, Vaccines and Specialty segments, operating manufacturing facilities at Nashik and Thane, supported by 20 CMOs and regional commercial hubs serving HCPs, hospitals and retail channels nationwide. Q3 FY26 financials show revenue of ₹1,023 crore (+8.1% YoY), EBITDA of ₹368 crore with a 35.9% margin (up 520 bps YoY) and PAT before exceptional of ₹277 crore (+21.3%), driven by gross margin improvement, operating leverage and field productivity gains; the company reported a strong cash balance of ₹2,426 crore and EPS of ₹16.36 for the quarter. Portfolio transformation toward higher innovation is evident: GSK India is scaling oncology after RUBY-1 approval (Dec 2025) with launches like Jemperli and Zejula, expanding adult immunization via Shingrix (≈50k prescriptions in Q3, +80% YoY), while established vaccines hold ~20.5% value market share, signalling a strategic shift to specialty and vaccine-led growth. Commercial execution and reach are robust: in-market growth of ~10.5% and rep market growth of 8.6% with key promoted brands maintaining a ~27.6% market share; GSK reports 360k+ unique HCPs reached and ~4 million touchpoints, alongside product line extensions and packaging innovations supporting customer experience and brand momentum.
Over the past 52 weeks, Glaxosmithkline Pharmaceuticals Ltd has traded between a low of ₹2,220.00 and a high of ₹3,515.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Glaxosmithkline Pharmaceuticals Ltd has a market capitalization of approximately 42,208.36. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Glaxosmithkline Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 41.46 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 42,208.36 Cr, Glaxosmithkline Pharmaceuticals Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Glaxosmithkline Pharmaceuticals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Glaxosmithkline Pharmaceuticals Ltd is 41.46. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
GlaxoSmithKline Pharmaceuticals reported a consolidated net profit of ₹296 crore for the third quarter ended December 31, 2025, which is a 29% increase year-on-year.
The most significant announcement is the 'Biopharma Shakti' scheme, with a ₹10,000 crore outlay to make India a global hub for biopharma manufacturing, directly supporting R&D and production of biologics.
Bearish
3
Neutral
6
Bullish
5
Bearish
31
Neutral
6
Bullish
9
Bearish
28
Neutral
0
Bullish
4
Postal Ballot Notice
GlaxoSmithKline Pharmaceuticals has issued a postal ballot seeking shareholder approval to appoint Mr. Ronojit Biswas as Director and as Whole-time Director & Chief Financial Officer for a three‑year term from 1 Apr 2026 to 31 Mar 2029; e‑voting 9 Mar–8 Apr 2026.
Postal Ballot Notice
GlaxoSmithKline Pharmaceuticals Ltd. issued a postal ballot seeking shareholder approval to appoint Mr. Ronojit Biswas as Whole‑time Director & Chief Financial Officer for 3 years (1 Apr 2026–31 Mar 2029); remote e‑voting 9 Mar–8 Apr 2026.
Regulatory Filing - Tax Demand
GlaxoSmithKline Pharmaceuticals received a Maharashtra GST order dated 17 Feb 2026 demanding Rs.6,92,76,478 (Tax Rs.3,46,38,239; Penalty Rs.3,46,38,239; interest unquantified) for alleged non‑payment of GST on export of services; company states no impact on financial operations and will take appropriate action.
Regulatory Filing
GSK Pharmaceuticals received an order dated 17 Feb 2026 from the Additional Commissioner, Mumbai Central, demanding Rs 6,92,76,478 for Apr 2022–Mar 2023 alleging non‑payment of GST on export of services; company states no financial impact.
GlaxoSmithKline Pharmaceuticals Limited (GSK India) is a leading Indian subsidiary of GSK plc that researches, manufactures, markets and distributes prescription pharmaceuticals, vaccines and specialty medicines across General Medicines, Vaccines and Specialty segments, operating manufacturing facilities at Nashik and Thane, supported by 20 CMOs and regional commercial hubs serving HCPs, hospitals and retail channels nationwide.
Q3 FY26 financials show revenue of ₹1,023 crore (+8.1% YoY), EBITDA of ₹368 crore with a 35.9% margin (up 520 bps YoY) and PAT before exceptional of ₹277 crore (+21.3%), driven by gross margin improvement, operating leverage and field productivity gains; the company reported a strong cash balance of ₹2,426 crore and EPS of ₹16.36 for the quarter.
Portfolio transformation toward higher innovation is evident: GSK India is scaling oncology after RUBY-1 approval (Dec 2025) with launches like Jemperli and Zejula, expanding adult immunization via Shingrix (≈50k prescriptions in Q3, +80% YoY), while established vaccines hold ~20.5% value market share, signalling a strategic shift to specialty and vaccine-led growth.
Commercial execution and reach are robust: in-market growth of ~10.5% and rep market growth of 8.6% with key promoted brands maintaining a ~27.6% market share; GSK reports 360k+ unique HCPs reached and ~4 million touchpoints, alongside product line extensions and packaging innovations supporting customer experience and brand momentum.
Pharmaceuticals
Pharmaceuticals - Multinational
42,208 Cr
Low Risk
41.5
38.7
4.1
24.7
3,515.95
2,220.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
27015.00 | 57,170 Cr | 37.67 | 14.25 | 1.77 | 37.62 | 48.38 | 26.77 | |
2491.55 | 42,208 Cr | 41.46 | 24.72 | 2.17 | 55.94 | 74.64 | 27.86 | |
4804.00 | 22,045 Cr | 25.75 | 5.73 | 3.42 | 18.36 | 24.12 | 18.53 | |
8800.00 | 22,004 Cr | 109.51 | 27.54 | 0.36 | 28.93 | 37.48 | 12.44 | |
4417.00 | 10,392 Cr | 42.38 | 27.06 | 0.00 | 62.53 | 75.60 | 43.89 | |
3672.00 | 8,457 Cr | 21.35 | 9.83 | 3.18 | 42.11 | 52.41 | 25.64 | |
4880.50 | 8,124 Cr | 27.60 | 13.11 | 2.55 | 49.51 | 65.17 | 32.81 |
